PPT-Future directions: Can we improve outcomes in relapsed/refractory DLBCL or aggressive

Bertrand Coiffier Service d Hématologie Hospices Civils de Lyon Equipe  Pathologie des Cellules Lymphoïdes  UMR 5239 CNRS UCB ENS HCL The Lymphoma Study Association One question lot of possibilities. Topics. Current Treatment Options for Relapsed/Refractory Multiple Myeloma. Topics. Relapsed/Refractory MM. Treatment Goals and Strategies. Relapsed/Refractory MM. Exposure to Stem Cell Toxic Agents Not An Issue for Most Patients . 5 Multiple Myeloma SANDRA E. KURTIN, RN, MS, AOCN Ruben Niesvizky. Myeloma Center. Myelomacenter.org. run9001@med.cornell.edu. Multiple Myeloma: Natural History of Disease. Durie B; International Myeloma Foundation. . Concise review of the disease and treatment options: multiple myeloma. 2011/2012 edition;. Hodgkin Lymphoma. Program Objectives. Brentuximab Vedotin in Hodgkin Lymphoma. Brentuximab Vedotin in Patients With R/R HL. Brentuximab Vedotin: Adverse Events . Nivolumab in Relapsed/Refractory HL. Pembrolizumab in Relapsed/Refractory HL. therapy in relapsed/refractory myeloma: . A UK multi-centre experience. Neil Rabin. Consultant Haematologist. o. n behalf of Dr Nicola . Maciocia. University College London Hospitals, UK. 4. th. November 2015. Prepared by: Forging a Comprehensive Initiative to Improve Birth Outcomes and Reduce Infant Mortality in [State] Adapted from AMCHP Birth Outcomes Compendium Tools What to expect this morning and afternoon Case Discussion A 64-year old woman diagnosed with monoclonal gammopathy of undetermined significance (MGUS ) in September 2015 She has been monitored over time and has had a slight increase in her proteins. T. ransplant . in CR on . B. rentuximab. . V. edotin. : . Allo. . Transplant . or . Maintenance . T. herapy. ?. Anas Younes, M.D.. Memorial Sloan Kettering Cancer Center. Overall Survival. <1990 median 1.9 yrs. Program Goals. DLBCL Subtypes . 2008 WHO Classification. Other DLBCL Variants. Dissecting DLBCL into Molecularly and Clinically Distinct Subgroups by Gene Expression Profiling. Outcomes Based on DLBCL Subtype Using Gene Expression Profiling. Jonathon B. Cohen, MD. Dept of . Hematology. /Medical Oncology. Co-Director . Lymphoma Program. Relapsed aggressive . nhl. associated with shortened survival. Scholar-1 (Crump et al, Blood 2017). Martin et al, Blood 2016. Chimeric Antigen Receptor Tcell TherapyClinical Guideline Effective August 4, 2022 ��Table of Contents��THIS DOCUMENT IS PROPRIETARY AND CONFIDENTIAL TO OPTUMUnauthorized u Helpline: 800 500 9976 | helpline@lymphoma.org Understanding LymphomaDiffuse Large B-Cell Lymphoma: Relapsed/Refractory Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin l (PMAL) Consortium and Associated Trials. 2016. CONFIDENTIAL. The new name for . Leukaemia. & Lymphoma Research. Tackling Diffuse Large B-cell Lymphoma. 2. Clinical Problem. Standard of care, RCHOP, results in cure rates around 75%. Diffuse Large B Cell Lymphoma. Foroud. . shahbazi. . Pharm.D. Introduction . Diffuse large B cell lymphoma (DLBCL) is the most common form . of aggressive . NHL accounting for approximately 30%-40% of cases.